Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections

Summary

SHIFT-2 is a national, multi-center, non-randomized, open label trial of aflibercept in patients with wet age related macular degeneration who have incomplete response with routineranibizumab treatment.

Timeline

Start

2014-04-17

Primary completion

2017-02-21

Completion

2017-02-21

Outcome

Outcome not reported

Stopped (Enrollment): “Inadequate enrollment due to investigational product becoming newly available on the Canadian market soon after study start”

Drugs

Indications